🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Compliance to MDT recs in OMD pts: 👉83.7% of MDT recommendations correctly implemented 👉Reasons for major deviations: physician decision, patient comorbidity or patient decision. 👉Major deviations associated with more than one distant met and worse OS doi.org/10.1016/j.ctro…

🔥A 9-year follow-up from the RADICALS-HD trial showed no significant difference in metastasis-free survival among prostate cancer patients receiving no ADT, 6-month ADT, or 24-month ADT after postoperative radiotherapy. ✅492 patients ✅10 years, 80% (no ADT), 77% (6-month

3 Ottobre, Lugano LAC – 1° Workshop di Genetica Oncologica in Ticino Per iscrizioni eventi.eoc.ch/oncogenetica/ Esperti svizzeri discuteranno la gestione dei pazienti a rischio genetico e familiare per carcinoma prostatico, renale e mammario. Supportato da SAKK

You’re still eligible for the 40% discount! Sign up now + collect CME credits at #EMUC24! Register now 👉 emuc.org/how-to-registe… ✅13 Plenary Sessions ✅EAU Section of Urological Imaging meeting ✅Special guest lecture ✅ESUP Symposium ✅FALCON workshop ESMO - Eur. Oncology ESTRO

8 Gy single fx liver RT + BSC improves liver pain control compared to BSC in painful hepatic cancer: the CCTG HE1 trial thelancet.com/journals/lanon…

The endless debate in patients with BCR after radical treatment: Do Not EMBARK on When, If the Answer Is How | Journal of Clinical Oncology . ascopubs.org/doi/10.1200/JC… Gianluca Giannarini

Just in The Lancet Oncology 👉Zr-girentuximab PET–CT is highly accurate for detecting ccRCC #kidneycancer (like PSMA-PET in prostate ca) Congrats, Brian Brian Shuch, MD et al, on these practice-impacting data. Open access👉tinyurl.com/4cwkm8u5 Michael Morris OncoAlert UroToday.com

⚡️ Long-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancer #BladderCancer BJU International bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bj…

#PACE A published in European Urology! SBRT vs Radical prostatectomy. Spread the word #SBRT should be discussed with eligible patients ⁦Dr Shaun Tolan⁩ Alison Tree 💙⁩ ⁦Clive Peedell⁩ Dr. Andrew Loblaw⁩ ⁦Prof Emma Hall⁩ Prof Joe O'Sullivan⁩ authors.elsevier.com/sd/article/S03…

TOPGEAR: In a trial comparing chemotherapy and preoperative chemoradiotherapy with perioperative chemotherapy in patients with resectable gastric or GE junction cancer, no significant difference in overall survival was noted. Full trial results: nej.md/4gg4gqv #ESMO24

RADIO Trial: Another point for weekly cisplatin + RT in HPV+ LASCCHN: •Hearing impairment (>grade 2) at 1 year: 40.8% (weekly) vs 64.0% (q3weekly) (p=0.027) 👂🧏 •Tinnitus: 73.5% (weekly) vs 92.0% (q3weekly) 🔔 #ESMO2024 #radiotherapy

PFS and OS advantage of radium-223 + Enza vs Enza alone in metastatic prostate cancer—-new combo on the horizon —congrats silke gillessen and PEACE-3 team. No increased SREs! ESMO - Eur. Oncology #ESMO2024

Outstanding talk from silke gillessen elegantly presenting PEACE-3 phase 3 trials first results. Adding 6 cycles of Ra223 to enzalutamide as first-line therapy for mCRPC showed significant rPFS improvement + significant OS benefit #ESMO24 ESMO - Eur. Oncology OncoAlert UroToday.com

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial - The Lancet thelancet.com/journals/lance…

Major congrats to my friend Dr Sofia Rivera on the HypoG-01 just presented at #ESMO2024 Hypofractionation not inferior to conventional fractionation for #BreastCancer with nodal RT. ✅Similar toxicity ✅Similar efficacy (BCSM OS LRFS DMFS) 3 weeks is the way to go!

Perioperative durvalumab + neoadjuvant chemo & cystectomy in operable bladder cancer significantly delays (HR 0.68) event free survival and a 25% reduction in the risk of death. 10% ⬆️ pCR. It’s the 1st time immune therapy has an OS benefit in muscle invasive UC #ESM024 NEJM

Transdermal estradiol as a new option for testosterone lowering vs LHRHa : similar MFS & OS but different toxicity than LHRHa (less hot flashes, higher bone mineral density...) Open Qs: 1. efficacy vs antagonists 2. combination with other drugs (ARPI, PARPi) or RT #ESMO2024

Prof Silke Gillessen silke gillessen presenting at #ESMO24 the results of stampede Arm K. Addition of Metformin has a clear benefit on metabolic effects on the long term. Look into the high volume subgroup outcomes in detail, interesting results!

Thomas Kennedy leads 10y prostate #SBRT outcomes from 3 different prospective studies now epub at #RedJ IJROBP - The Red Journal doi.org/10.1016/j.ijro… Great biochemical control to 15 years and only 1% chance of mets! Note 10% of UIR pts received ADT and none had whole pelvic RT (-> #PR24)

Pleased to share the newest MARCAP publication, out in European Urology -- the TRANSPORT analysis of T recovery after ADT for localized PCa, led by Wee Loon Ong and Tahmineh Romero Free share link: authors.elsevier.com/a/1joOX14kplyz…